• 1
    IARC Monographs. Arsenic and arsenic compounds. Overall evaluation of carcinogenicity. An updating of IARC monographs, vols. 1–42. Suppl. 7, Lyon: IARC, 1987. 1006.
  • 2
    DiPaolo JA, Casto BC. Quantitative studies of in vitro morphological transformation of Syrian hamster cells by inorganic metal salts. Cancer Res 1979;39: 100813.
  • 3
    Lee TC, Oshimura M, Barrett JC. Comparison of arsenic-induced cell transformation, cytotoxicity, mutation and cytogenetic effects in Syrian hamster embryo cells in culture. Carcinogenesis 1985;6: 14216.
  • 4
    Bertolero F, Pozzi G, Sabbioni E, Saffiotti U. Cellular uptake and metabolic reduction of pentavalent to trivalent arsenic as determinants of cytotoxicity and morphological transformation. Carcinogenesis 1987;8: 8038.
  • 5
    Landolph JR. Molecular mechanisms of transformation of C3H/10T1/2 C18 mouse embryo cells and diploid human fibroblasts by carcinogenic metal compounds. Environ Health Perspect 1994;102: 11925.
  • 6
    Zhao CQ, Young MR, Diwan BA, Coogan TP, Waalkes MP. Association of arsenic-induced malignant transformation with DNA hypomethylation and aberrant gene expression. Proc Natl Acad Sci USA 1997;94: 1090712.
  • 7
    Barrett JC, Thomassen DG. Use of quantitative cell transformation assays in risk estimation. In: VoukVB, ButlerGC, HoelDG, PeakallDB, eds. Methods for estimating risk of chemical injury: human and non-human biota and ecosystems. New York: John Wiley & Sons, 1985. 20134.
  • 8
    Barrett JC, Ts'o POP. Evidence for the progressive nature of neoplastic transformation in vitro. Proc Natl Acad Sci USA 1978;75: 37615.
  • 9
    Tsutsui T, Maizumi H, Barrett JC. Colcemid-induced neoplastic transformation and aneuploidy in Syrian hamster embryo cells. Carcinogenesis 1984;5: 8993.
  • 10
    Tsutsui T, Suzuki N, Ohmori M. Sodium fluoride–induced morphological and neoplastic transformation, chromosome aberrations, sister chromatid exchanges, and unscheduled DNA synthesis in cultured Syrian hamster embryo cells. Cancer Res 1984;44: 93841.
  • 11
    Moore MM, Harrington-Brock K, Doerr CL. Relative genotoxic potency of arsenic and its methylated metabolites. Mutat Res 1997;386: 27990.
  • 12
    Hei TK, Liu SX, Waldren C. Mutagenicity of arsenic in mammalian cells: role of reactive oxygen species. Proc Natl Acad Sci USA 1998;95: 81037.
  • 13
    Lee TC, Huang R-Y, Jan KY. Sodium arsenite enhances the cytotoxicity, clastogenicity, and 6-thioguanine-resistant mutagenicity of ultraviolet light in Chinese hamster ovary cells. Mutat Res 1985;148: 839.
  • 14
    Dong JT, Luo XM. Arsenic-induced DNA-strand breaks associated with DNA–protein crosslinks in human fetal lung fibroblasts. Mutat Res 1993;302: 97102.
  • 15
    Dong JT, Luo XM. Effects of arsenic on DNA damage and repair in human fetal lung fibroblasts. Mutat Res 1994;315: 115.
  • 16
    Ramírez P, Eastmond DA, Laclette JP, Ostrosky-Wegman P. Disruption of microtubule assembly and spindle formation as a mechanism for the induction of aneuploid cells by sodium arsenite and vanadium pentoxide. Mutat Res 1997;386: 2918.
  • 17
    Lee TC, Tanaka N, Lamb PW, Gilmer TM, Barrett JC. Induction of gene amplification by arsenic. Science 1988;241: 7981.
  • 18
    Ramírez P, Del Razo LM, Gutierrez-Ruíz MC, Gonsebatt ME. Arsenite induces DNA–protein crosslinks and cytokeratin expression in the WRL-68 human hepatic cell line. Carcinogenesis 2000;21: 7016.
  • 19
    Huang SC, Lee TC. Arsenite inhibits mitotic division and perturbs spindle dynamics in HeLa S3 cells. Carcinogenesis 1998;19: 88996.
  • 20
    Hamadeh HK, Vargas M, Lee E, Menzel DB. Arsenic disrupts cellular levels of p53 and mdm 2: a potential mechanism of carcinogenesis. Biochem Biophys Res Commun 1999;263: 4469.
  • 21
    Barrett JC, Bias NE, Ts'o POP. A mammalian cellular system for the concomitant study of neoplastic transformation and somatic mutation. Mutat Res 1978;50: 12136.
  • 22
    McLimans WF, Davis EV, Glover FL, Rake GW. The submerged culture of mammalian cells: the spinner culture. J Immunol 1957;79: 42833.
  • 23
    Barrett JC, Crawford BD, Mixter LO, Schectman LM, Ts'o POP, Pollack P. Correlation of in vitro growth properties and tumorigenicity of Syrian hamster cell lines. Cancer Res 1979;39: 150410.
  • 24
    Chen H, Liu J, Merrick BA, Waalkes MP. Genetic events associated with arsenic-induced malignant transformation: applications of cDNA microarray technology. Mol Carcinog 2001;30: 7987.
  • 25
    Chen H, Liu J, Zhao CQ, Diwan BA, Merrick BA, Waalkes MP. Association of c-myc overexpression and hyperproliferation with arsenite-induced malignant transformation. Toxicol Appl Pharmacol 2001;175: 2608.
  • 26
    Nambu S, Inoue K, Sasaki H. Site-specific hypomethylation of the c-myc oncogene in human hepatocellular carcinoma. Jpn J Cancer Res 1987;78: 695704.
  • 27
    Rao PM, Antony A, Rajalakshmi S, Sarma DSR. Studies on hypomethylation of liver DNA during early stages of chemical carcinogenesis in rat liver. Carcinogenesis 1989;10: 9337.
  • 28
    Singal R, Ginder GD. DNA methylation. Blood 1999;93: 405970.
  • 29
    Mass MJ, Wang L. Arsenic alters cytosine methylation patterns of the promoter of the tumor suppressor gene p53 in human lung cells: a model for a mechanism of carcinogenesis. Mutat Res 1997;386: 26377.
  • 30
    Vogt BL, Rossman TG. Effects of arsenite on p53, p21 and cyclin D expression in normal human fibroblasts—a possible mechanism for arsenite's comutagenicity. Mutat Res 2001;478: 15968.